Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Patients are eligible if they have one of the following types of cancer:
The following patients are not eligible:
For study information, contact: Pfizer CT.gov Call Center 1-800-718-1021 or by email.
The purpose of the study is to examine the anti-tumor activity and safety of the immuno-onology agent, Avelumab in combination with the PARP inhibitor, talazoparib in patients with locally advanced or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, castration resistant prostate cancer (CRPC)solid tumors, non-small cell lung cancer (NSCLC), and urothelial cancer (UC).
This is a nonrandomized, open label study. All participants will receive the study agents, avelumab (intravenous) and talazoparib (oral).
MD Anderson Cancer Center